Skip to main content
MedPathMedPath Home
Clinical Trials/NCT01713075
NCT01713075
Completed
Not Applicable

Symbicort Turbuhaler 30/60 Special Clinical Experience Investigation for Long-term Use for COPD Patients

AstraZeneca1 site in 1 country1,183 target enrollmentNovember 2012
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsChronic Obstructive Pulmonary Disease

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Chronic Obstructive Pulmonary Disease
Sponsor
AstraZeneca
Enrollment
1183
Locations
1
Primary Endpoint
Adverse event incidence
Status
Completed
Last Updated
9 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSitesSimilar Trials

Overview

Brief Summary

The purpose of the investigation is to confirm the safety and efficacy in long-term use of Symbicort Turbuhaler in patients with Chronic obstructive pulmonary disease (COPD) under the post-marketing actual use.

Detailed Description

Symbicort Turbuhaler 30/60 Special Clinical Experience Investigation for long-term use for COPD patients

Registry
clinicaltrials.gov
Start Date
November 2012
End Date
December 2015
Last Updated
9 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • •Among patients treated with Symbicort Turbuhaler due to chronic obstructive pulmonary disease(COPD), those who received the drug for the first time.

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Adverse event incidence

Time Frame: 1 year

Secondary Outcomes

  • Clinical questionnaire about chronic obstructive pulmonary disease(CCQ)(At baseline, Week 12, Week 26, 1 year)

Study Sites (1)

Loading locations...

Similar Trials

Completed
Not Applicable
Symbicort Turbuhaler 30/60 Specific Clinical Experience InvestigationBronchial Asthma
NCT01232335AstraZeneca1,500
Completed
Not Applicable
Clinical Experience Investigation of Symbicort Turbuhaler as Maintenance Therapy and Reliever TherapyBronchial Asthma
NCT01711840AstraZeneca2,409
Completed
Phase 3
Comparison of the Efficacy/Safety of Symbicort® Turbuhaler®,Seretide™ Diskus™ 50/500 µg & Terbutaline Turbuhaler® 0.4 mgAsthma
NCT00242775AstraZeneca2,100
Completed
Not Applicable
Symbicort Turbuhaler 30/60 Clinical Experience InvestigationBronchial Asthma
NCT01232348AstraZeneca3,643
Completed
Phase 3
A Safety and Efficacy Study of Symbicort Turbuhaler Compared With Standard Chronic Obstructive Pulmonary Disease (COPD) Treatment in JapanChronic Obstructive Pulmonary Disease
NCT01070784AstraZeneca328